These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Please note that the physiological activity of the ingredient(s) described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient(s) described herein are responsible for determining whether claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.



  • Liu W et al. Pomegranate [Pomella®] phenolics inhibit formation of advanced glycation  endproducts by scavenging reactive carbonyl species. Food Funct. 2014 Sep 11. 5: 2996-3004. DOI: 10.1039/c4fo00538d - Pomella® phenolics inhibit the formation of a biologically relevant oxidative stress marker called Advanced Glycation Endproducts, or AGE.

  • Henning SM et al. Variability in the antioxidant activity of dietary supplements from pomegranate  [Pomella®], milk thistle, green tea, grape seed, goji, and acai: Effects of in  vitro digestion. J Agric Food Chem. 2014 Apr 18. 62: 4313-4321. DOI: 10.1021/jf500106r - Pomella® ranked highest in antioxidant activity across a number of assays including ORAC, TEAC, FRAP, and DPPH, compared to 26 other antioxidant products.

  • Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. J Agric Food Chem. 2008 Feb 27. 54(4): 1415-1422. EPub 2008 Jan 26.
  • Heber D et al. Safety and antioxidant activity of a pomeganate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size. J Agric Food Chem. 2007 Sep 21. 55(24): 10050-10054. EPub 2007 Oct 30.



  • Seeram NP et al. Pomegranate juice extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food. 2008 Jan 23. 11(2): 390-394. DOI: 10.1089/jmf.2007.650

  • Mertens-Talcott SU et al. Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum  L) polyphenols after ingestion of a standardized extract [Pomella®] in healthy  human volunteers. J Agric Food Chem. 2006 Sep 6. 54(23): 8956-8961. EPub 2006 Oct 13. DOI: 10.1021/jf061674h - Pomella’s patented extraction process delivers an ellagitannin rich prole standardized to punicalagin content. A single dose of Pomella led to a significant 32% increase of antioxidant activity in the blood. Bioactive punicalagin derived metabolites were detected in half an hour after dosing.

  • Seeram NP et al. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr. 2006 Jul 10. 136: 2481-2485.

  • Seeram NP et al. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from promegranate (Punica granatum L) juice. Clinica Chimica Acta. 2004 Apr 30. 348: 63-68. DOI: 10.1016/j.cccn.2004.04.029

  • Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr. 2003 Jan. 42(1): 18-28.



  • Liu W et al. Development of a neuroprotective potential algorithm for medicinal plants.  University of Rhode Island. Neurochem Int. 29 Sep 2016. 100: 164-177. - As part of a strategy to help guide the selection and evaluation of medicinal plant candidates for their neuroprotective potential, researchers at University of Rhode Island developed a Neuroprotective Potential Algorithm (NPA) by evaluating twenty-three standardized and chemically characterized Ayurvedic medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl stress, protein glycation, amyloid beta (Aβ) brillation, acetylcholinesterase (AChE) inhibition, and neuroinammation.

  • Goyal R et al. Antioxidative effect of Punica granatum (pomegranate) on biochemical parameters  in patients with T2D and MI: A double blind placebo controlled trial. Int J Adv Res. 2016 May. Vol 4(Issue 5): 857-864. DOI: 10.21474/IJAR01 - Patients with were administered 300mg Pomella® daily for 30-days as an adjuct treatment showed significant improvements in key metabolic biomarkers. Especially signfiicant decreases in blood glucose and HbA1c were seen compared to baseline.

  • Goyal R et al. An antioxidative effect of Punica granatum (pomegranate) on biochemical  parameters in patients with MI: A double blind placebo controlled trial.  Eur J Biomed Pharma Sci. 2016 Apr 30. Vol 3(Issue 5): 662-667. - Patients were administered 300mg Pomella® daily for 30-days as an adjuct treatment showed signficiant improvements in biomedical parameters such as HDL, OX-LDL, serum homocystein, hs-CRP, and others.

  • Yuan T et al. Pomegranate’s neuroprotective effects are mediated by urolithins, its  ellagitannin-gut microbial derived metabolites.  ACS Chem Neurosci. 2015 Nov 11. DOI: 10.1021/acschemneuro.5b00260 - Urolithins, gut microbial metabolites of ellagitannins, fullled in silico criteria required for BBB permeability, and prevented β-amyloid fibrillation in vivo. Moreover, urolithins not only prevented β-amyloid fibrillation in vitro, it also protected Caenorhabditis elegans from amyloid β1−42 induced neurotoxicity and paralysis, supporting its neuroprotective effect.

  • Ahmed AH et al. Pomegranate extract modulates processing of amyloid-β precursor protein in an  aged animal model.  Current Alz Res. 2014. 11(9). - Pomella® was shown to impact cognitive function and markers of healthy brain aging in an aged transgenic AD model. Findings support a specific anti-amyloidgenic mechanism of Pomella.

  • Jean-Giles D et al. Inhibitory effects of polyphenol punicalagin on type-II collagen degradation in  vitro and in vivo. Chem-Bio Inter. 2013 Jun 20. 205: 90-99. EPub 2013 Jul 2. DOI: 10.1016/j.cbi.2013.06.018 - Pomella’s punicalagins were shown to inhibit collagen degradation and supported anti-inflammatory effects; indicating possible joint health support opportunities.

  • DiSilvestro RA et al. Pomegranate extract mouth rinsing effects on saliva measures relevant to  gingivitis risk. Phytother Res. 2009. 23: 1123-1127. EPub 2009 Jan 23. DOI: 10.1002/ptr.2759 - Pomella® mouthwash administered 3x daily aected saliva readings for antioxidant, anti-inflammatory, antibacterial, and bacterial enzyme inhibition compared to placebo. Further Pomella reduced total protein count, which is associated with plaque forming bacteria.

  • Pacheco-Palencia LA et al. Protective effects of standardized pomegranate (Punica granatum L) polyphenolic  extract in ultraviolet-irradiated human skin broblasts. J Agric Food Chem. 2008 Jul 18. EPub 2008 Aug 22. DOI: 10.1021/jf8005307 - Pomella® was shown to be effective at protecting human skin broblasts from cell death following UVA and UVB exposure, while increasing the intracellular antioxidant capacity, and reducing generation of intracellular reactive oxygen species (ROS) after UV exposure.

  • Patel C et al. Safety assessment of pomegranate fruit extract: Acute and subchronic toxicity  studies. Food Chem Toxicol. 2008 Apr 24. 46: 2728-2735. DOI: 10.1016/j.fct.2008.04.035 - Results of this trial indicated that no observed adverse effect level (NOAEL) at the highest tested level of Pomella®, was 600 mg/kg body weight/day.

  • Shiner M et al. Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic antioxidants via PPAR gamma and AP-1 pathway activation. Atherosclerosis. 2007 Dec. 195(2): 313-321. EPub 2007 Feb 12.

  • deNigris F et al. The influence of pomegranate fruit extract in comparison to regular pomegranate juice and seed oil on nitric oxide and arterial function in obese Zucker rats. Nitric Oxide. 2007 Aug. 17(1): 50-54. EPub 2007 May 5.

  • Pomegranates for the prostate and the heart: Seeds of hope. Harv Med Health Watch. 2007 Apr. 11(9): 4-5. No Abstract Available.

  • deNigris F et al. Effects of a pomegranate fruit extract rich in punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed shear stress and atherogenesis. Cardiovasc Res. 2007 Jan 15. 73(2): 414-423.

  • Aviram M et al. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis. 2001. 158: 195-198.